The deal range was $30.00-$31.00. Leerink, TD Cowen, Guggenheim, Wells Fargo and LifeSci Capital acted as joint book running managers for the offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Rapt Therapeutics announces common stock offering, no amount given
- Rapt Therapeutics price target raised to $48 from $38 at Wells Fargo
- Rapt Therapeutics price target raised to $60 from $41 at Clear Street
- RAPT Therapeutics Reports Positive Phase 2 Trial Results
- Rapt Therapeutics price target raised to $58 from $35 at Barclays